Literature DB >> 1268863

Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

A Krishan, M Israel, E J Modest, E Frei.   

Abstract

Adriamycin-specific fluorescence appears slowly in living cells and is localized in nuclei and chromosomes. N-Trifluoroacetyladriamycin-14-valerate, a recently synthesized adriamycin analog, differs from the parent anthracycline in the rapid appearance of its fluorescence in the cytoplasm of living cells and the lack of any fluorescent binding to nuclei and chromosomes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1268863

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes.

Authors:  E Chacon; R Ulrich; D Acosta
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

Review 2.  Valrubicin.

Authors:  S V Onrust; H M Lamb
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

3.  Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro.

Authors:  M Israel; J M Idriss; Y Koseki; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 5.  Mutagenic effects of some anticancer antibiotics.

Authors:  B K Vig
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 7.  Cancer chemotherapy: new developments and changing concepts.

Authors:  S K Carter
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

8.  Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

Authors:  T W Sweatman; R F Parker; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Radioactive species in rat urines and tissues after [14C] AD 32 administration.

Authors:  G Zini; G P Vicario; M Lazzati; F Arcamone
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.